You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》建銀國際升信達生物(01801.HK)目標至100元 維持「跑贏大市」
阿思達克 07-08 10:15
建銀國際研究報告指,信達生物(01801.HK)於研發會議上表示,有信心可達成2027年末前銷售額200億元人民幣(下同)的目標,而該行預期爲229億元。另外,公司亦有信心2023年末前會有最少5款關鍵分子可進行第3期多區域臨牀試驗,並相信新一代雙特異性抗體與抗體藥物偶聯物(ADC)的聯合療法將成爲免疫腫瘤療法的新趨勢和方向。 公司於6月公佈其IBI363(Mazdutide)獲批於國內用於減重病人,時間表符合該行預期。因此,該行將2025、26及27年的總收入預測分別上調1%、3%及4%,至124億、185億及229億元;將Mazdutide藥物於2034年末前的最高銷售額預測由64億元上調至78億元。2025、26及27年的經調整盈利分別上調4%、8%及1%,至4.57億元、20億元及49億元。 該行認爲,短期催化劑包括大中華地區以外的潛在對外授權,以及公司關鍵臨牀階段藥物有積極的臨牀結果;將公司列爲行業首選,目標價由90港元升至100港元,維持「跑贏大市」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account